Literature DB >> 10570192

A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy.

E A Burton1, J M Tinsley, P J Holzfeind, N R Rodrigues, K E Davies.   

Abstract

Duchenne muscular dystrophy (DMD) is an inherited muscle-wasting disease caused by the absence of a muscle cytoskeletal protein, dystrophin. We have previously shown that utrophin, the autosomal homologue of dystrophin, is able to compensate for the absence of dystrophin in a mouse model of DMD; we have therefore undertaken a detailed study of the transcriptional regulation of utrophin to identify means of effecting its up-regulation in DMD muscle. We have previously isolated a promoter element lying within the CpG island at the 5' end of the gene and have shown it to be synaptically regulated in vivo. In this paper, we show that there is an alternative promoter lying within the large second intron of the utrophin gene, 50 kb 3' to exon 2. The promoter is highly regulated and drives transcription of a widely expressed unique first exon that splices into a common full-length mRNA at exon 3. The two utrophin promoters are independently regulated, and we predict that they respond to discrete sets of cellular signals. These findings significantly contribute to understanding the molecular physiology of utrophin expression and are important because the promoter reported here provides an alternative target for transcriptional activation of utrophin in DMD muscle. This promoter does not contain synaptic regulatory elements and might, therefore, be a more suitable target for pharmacological manipulation than the previously described promoter.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570192      PMCID: PMC24184          DOI: 10.1073/pnas.96.24.14025

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Specificity of expression of the muscle and brain dystrophin gene promoters in muscle and brain cells.

Authors:  E Barnea; D Zuk; R Simantov; U Nudel; D Yaffe
Journal:  Neuron       Date:  1990-12       Impact factor: 17.173

2.  Translational discrimination of mRNAs coding for human insulin-like growth factor II.

Authors:  F C Nielsen; S Gammeltoft; J Christiansen
Journal:  J Biol Chem       Date:  1990-08-15       Impact factor: 5.157

3.  Muscle and neural isoforms of agrin increase utrophin expression in cultured myotubes via a transcriptional regulatory mechanism.

Authors:  A O Gramolini; E A Burton; J M Tinsley; M J Ferns; A Cartaud; J Cartaud; K E Davies; J A Lunde; B J Jasmin
Journal:  J Biol Chem       Date:  1998-01-09       Impact factor: 5.157

4.  Local transcriptional control of utrophin expression at the neuromuscular synapse.

Authors:  A O Gramolini; C L Dennis; J M Tinsley; G S Robertson; J Cartaud; K E Davies; B J Jasmin
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

Review 5.  Increasing complexity of the dystrophin-associated protein complex.

Authors:  J M Tinsley; D J Blake; R A Zuellig; K E Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

6.  Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle.

Authors:  A Clerk; G E Morris; V Dubowitz; K E Davies; C A Sewry
Journal:  Histochem J       Date:  1993-08

7.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

8.  Primary structure of dystrophin-related protein.

Authors:  J M Tinsley; D J Blake; A Roche; U Fairbrother; J Riss; B C Byth; A E Knight; J Kendrick-Jones; G K Suthers; D R Love
Journal:  Nature       Date:  1992-12-10       Impact factor: 49.962

9.  The utrophin and dystrophin genes share similarities in genomic structure.

Authors:  M Pearce; D J Blake; J M Tinsley; B C Byth; L Campbell; A P Monaco; K E Davies
Journal:  Hum Mol Genet       Date:  1993-11       Impact factor: 6.150

10.  Dystrophin is transcribed in brain from a distant upstream promoter.

Authors:  F M Boyce; A H Beggs; C Feener; L M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more
  28 in total

1.  Genome-wide genetic associations with IFNγ response to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2012-06-03       Impact factor: 4.132

2.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Authors:  Hsin-Kai Liao; Fumiyuki Hatanaka; Toshikazu Araoka; Pradeep Reddy; Min-Zu Wu; Yinghui Sui; Takayoshi Yamauchi; Masahiro Sakurai; David D O'Keefe; Estrella Núñez-Delicado; Pedro Guillen; Josep M Campistol; Cheng-Jang Wu; Li-Fan Lu; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

3.  The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy.

Authors:  K J Perkins; E A Burton; K E Davies
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

4.  Molecular characterization of a de novo 6q24.2q25.3 duplication interrupting UTRN in a patient with arthrogryposis.

Authors:  Anne-Claude Tabet; Azzedine Aboura; Marion Gérard; Marion Pilorge; Céline Dupont; Jean-François Gadisseux; Nadège Hervy; Eva Pipiras; Andrée Delahaye; Samia Kanafani; Alain Verloes; Brigitte Benzacken; Catalina Betancur
Journal:  Am J Med Genet A       Date:  2010-07       Impact factor: 2.802

5.  Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders.

Authors:  Daria Wojtal; Dwi U Kemaladewi; Zeenat Malam; Sarah Abdullah; Tatianna W Y Wong; Elzbieta Hyatt; Zahra Baghestani; Sergio Pereira; James Stavropoulos; Vincent Mouly; Kamel Mamchaoui; Francesco Muntoni; Thomas Voit; Hernan D Gonorazky; James J Dowling; Michael D Wilson; Roberto Mendoza-Londono; Evgueni A Ivakine; Ronald D Cohn
Journal:  Am J Hum Genet       Date:  2015-12-10       Impact factor: 11.025

6.  Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy.

Authors:  Stefanie Endesfelder; Sabine Bucher; Alexander Kliche; Regina Reszka; Astrid Speer
Journal:  J Mol Med (Berl)       Date:  2003-05-06       Impact factor: 4.599

Review 7.  Dystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies.

Authors:  Caroline Perronnet; Cyrille Vaillend
Journal:  J Biomed Biotechnol       Date:  2010-06-17

8.  Dynamic functional modules in co-expressed protein interaction networks of dilated cardiomyopathy.

Authors:  Chen-Ching Lin; Jen-Tsung Hsiang; Chia-Yi Wu; Yen-Jen Oyang; Hsueh-Fen Juan; Hsuan-Cheng Huang
Journal:  BMC Syst Biol       Date:  2010-10-15

Review 9.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599

10.  Identification of transcripts from a subtraction library which might be responsible for the mild phenotype in an intrafamilially variable course of Duchenne muscular dystrophy.

Authors:  Marco Sifringer; Birgit Uhlenberg; Stefanie Lammel; Rita Hanke; Benjamin Neumann; Arpad von Moers; Ina Koch; Astrid Speer
Journal:  Hum Genet       Date:  2003-11-05       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.